Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

This study is testing a drug called zanzalintinib in people with advanced thyroid cancer that has grown into nearby tissues or lymph nodes and needs to be shrunk before surgery can be attempted. The aim is to make previously inoperable thyroid cancers resectable (able to be removed surgically). **You may be eligible if...** - You are 18 or older - You have differentiated thyroid cancer, poorly differentiated thyroid cancer, or non-RET medullary thyroid cancer - Your cancer is advanced locally (has grown into surrounding tissue or lymph nodes) or recurrent/residual and complex to remove surgically - A surgeon has assessed your surgery as moderately to extremely difficult - You have not yet undergone surgery for this diagnosis **You may NOT be eligible if...** - You have a RET gene mutation (for medullary thyroid cancer — a different targeted therapy exists) - Your cancer can already be surgically removed without major complications - You have had prior treatment with similar targeted drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.